- Home
- SNTG vs CDT Comparison
SNTG vs CDT Comparison
Compare SNTG & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- CDT
- Stock Information
- Founded
- SNTG 2009
- CDT 2019
- Country
- SNTG China
- CDT United States
- Employees
- SNTG N/A
- CDT N/A
- Industry
- SNTG Finance: Consumer Services
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- CDT Health Care
- Exchange
- SNTG Nasdaq
- CDT Nasdaq
- Market Cap
- SNTG 5.2M
- CDT 5.2M
- IPO Year
- SNTG 2021
- CDT N/A
- Fundamental
- Price
- SNTG $1.75
- CDT $0.69
- Analyst Decision
- SNTG
- CDT
- Analyst Count
- SNTG 0
- CDT 0
- Target Price
- SNTG N/A
- CDT N/A
- AVG Volume (30 Days)
- SNTG 12.2K
- CDT 1.4M
- Earning Date
- SNTG 04-25-2025
- CDT 05-13-2025
- Dividend Yield
- SNTG N/A
- CDT N/A
- EPS Growth
- SNTG N/A
- CDT N/A
- EPS
- SNTG N/A
- CDT N/A
- Revenue
- SNTG $146,472.00
- CDT N/A
- Revenue This Year
- SNTG N/A
- CDT N/A
- Revenue Next Year
- SNTG N/A
- CDT N/A
- P/E Ratio
- SNTG N/A
- CDT N/A
- Revenue Growth
- SNTG N/A
- CDT N/A
- 52 Week Low
- SNTG $1.65
- CDT $0.65
- 52 Week High
- SNTG $3.97
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- SNTG 42.69
- CDT 31.97
- Support Level
- SNTG $1.77
- CDT $0.65
- Resistance Level
- SNTG $1.85
- CDT $1.05
- Average True Range (ATR)
- SNTG 0.06
- CDT 0.14
- MACD
- SNTG -0.01
- CDT 0.07
- Stochastic Oscillator
- SNTG 2.14
- CDT 7.30
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.